The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IASLC TTLC 2024 | Developments in the management of EGFR-mutated NSCLC
Monica Chen, MD, Memorial Sloan Kettering Cancer Center, New York, NY, gives an overview of current updates in the treatment of EGFR-positive non-small cell lung cancer (NSCLC), including the Phase III MARIPOSA-2 trial (NCT04988295) of amivantamab plus chemotherapy with or without lazertinib, and the HERTHENA-Lung01 trial (NCT04619004) of patritumab deruxtecan, an antibody drug conjugate. This interview took place at 2024 Targeted Therapies of Lung Cancer Meeting (TTLC 2024) in Santa Monica, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
